Medco has reported $12 billion in excess revenue in its accounting records - 2002-07-08. Another major company in the U.S. is embroiled in a major financial scandal. According to the Wall Street Journal, a unit of the pharmaceutical giant Merck, one of the largest pharmaceutical institutions in the world, has shown at least $12 billion in excess revenue over what it has actually earned in its accounting records since 1999. According to the report, Medco, which is part of Merck, has counted payments made by patients for part of the costs of medications purchased from pharmacies that health insurance companies do not cover as its revenue, even though these payments are not typically made to pharmaceutical companies. Merck states that its accounting practices are in line with standard company practices, but the disclosure of this erroneous revenue report has cast further doubt on the management of large companies in the U.S. Yesterday, a subcommittee of the U.S. Senate released a report that severely criticized the energy trading company Enron, which went bankrupt. President Bush is expected to deliver a speech tomorrow in New York, the headquarters of major U.S. financial institutions, expressing his views on implementing stricter regulations regarding corporate officials.
Medco Reports $12 Billion Excess Revenue in Accounting Records
Medco, a subsidiary of Merck, has reported $12 billion in excess revenue in its accounting, raising concerns about financial practices in large U.S. companies. This revelation follows criticism of Enron's bankruptcy and is likely to prompt discussions on stricter corporate regulations by President Bush.
👥 Key Players
📰 What Happened
Medco reported $12 billion in excess revenue due to questionable accounting practices, raising concerns about financial transparency in large U.S. corporations. This comes amid ongoing scrutiny of corporate governance following the Enron scandal.
- Medco counted patient payments as revenue, which is not standard practice.
- The report coincides with a Senate subcommittee's criticism of Enron's financial practices.
💡 Why It Matters
📚 Background
The early 2000s saw a series of corporate scandals in the U.S., leading to significant regulatory changes aimed at increasing transparency and accountability in financial reporting.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 85%